1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders

• Váldodahkkit: Ondrej Benek (Dahkki), Lukas Hroch (Dahkki), Laura Aitken (Dahkki), Frank Gunn-Moore (Dahkki), Lucie Vinklarova (Dahkki), Kamil Kuca (Dahkki), Daniel I. Perez (Dahkki), Concepcion Perez (Dahkki), Ana Martinez (Dahkki), Zdenek Fisar (Dahkki), Kamil Musilek (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Several neurodegenerative disorders including Alzheimer's disease (AD) have been connected with deregulation of casein kinase 1 (CK1) activity. Inhibition of CK1 therefore presents a potential therapeutic strategy against such pathologies. Recently, novel class of CK1-specific inhibitors with N...